Verona Pharma

End of the list of the largest biotech companies in the UK is Verona Pharma, a clinical-stage biopharmaceutical company specializing in developing and commercializing new therapies for treating chronic respiratory disorders with high unmet medical needs. Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapeutic for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory properties in one compound.

The company's mission is to enhance the health and quality of life of millions suffering from chronic respiratory disorders. The company is led by a management team with a proven track record of discovering, developing, and commercializing respiratory medicines.

Ensifentrine (RPL554), its first-in-class development candidate, has the potential to give ease to patients suffering from respiratory disorders such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and asthma. Ensifentrine achieved statistically significant and clinically relevant lung function improvements in the ENHANCE-1 and ENHANCE-2 studies. Furthermore, in ENHANCE-1 and ENHANCE-2, ensifentrine significantly reduced the rate of COPD exacerbations.

Founded: 2005
Headquarters: London, UK
Website: https://www.veronapharma.com/